|Free Dividend Report|
|Stock Splits Calendar|
|IDRA Stock Split History|
|Preferred Stock Newsletter|
|IDRA Options Chain|
|Stock Message Boards|
Idera Pharmaceuticals (IDRA) has 1 split in our IDRA split history database. The split for IDRA took place on July 30, 2018. This was a 1 for 8 reverse split, meaning for each 8 shares of IDRA owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 125 share position following the split.
When a company such as Idera Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the IDRA split history from start to finish, an original position size of 1000 shares would have turned into 125 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Idera Pharmaceuticals shares, starting with a $10,000 purchase of IDRA, presented on a split-history-adjusted basis factoring in the complete IDRA split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-26.62%|
|About Idera Pharmaceuticals|
|Idera Pharmaceuticals is a biopharmaceutical company focused on the clinical development, and the commercialization, of drug candidates for rare disease indications characterized by patient populations with unmet medical needs. Co.'s focus is to identify and acquire rights to development and commercial stage rare disease programs through new business development opportunities, including additional alternatives. Co. is evaluating intratumoral tilsotolimod in combination with nivolumab, an anti-Progressive Disease 1 antibody marketed as Opdivo® by Bristol Myers Squibb Company, and ipilimumab for the treatment of multiple solid tumors in a multicohort trial. According to our IDRA split history records, Idera Pharmaceuticals has had 1 split.|
|IDRA Split History Table|
|07/30/2018||1 for 8|
|Healthcare Stock Splits|
|IDRA is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: IDRA shares outstanding history